COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
17 hedge funds and large institutions have $1.17M invested in COSCIENS Biopharma Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
17% more capital invested
Capital invested by funds: $996K → $1.17M (+$171K)
13% more funds holding
Funds holding: 15 → 17 (+2)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
46% less call options, than puts
Call options by funds: $14K | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$234K |
| 2 |
VF
Virtu Financial
New York
|
+$46.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$30.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$24K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33.6K |
| 2 |
Millennium Management
New York
|
-$21K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$1K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$550 |
CSCI Hedge Fund Activity: Q3 2018 in Review
17 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2018, worth a combined $1.17M — up 17% from $996K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CSCI positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $234K. The largest seller was Susquehanna International Group, cutting an estimated $33.6K.
- 17 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2018, up from 15 in Q2 2018.
- Funds reported $1.17M of COSCIENS Biopharma Inc. Common Stock stock for Q3 2018, up 17% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2018 and 3 closed out, a net change of +2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2018 was Morgan Stanley, an estimated $234K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2018 was Susquehanna International Group, an estimated $33.6K sold.
Based on aggregated 13F filings for Q3 2018.